An experimental drug designed by Belgian biotech group Galapagos to treat the bowel disease ulcerative colitis has failed medical trials and will be discontinued.
According to Reuters, the drug in question in GLPG1205. Galapagos stated that in trials it did not perform better than the placebo given to a separate group of patients.
This was enough for the company to discontinue their program for that disease. However, Galapagos will continue to test GLPG and how it might function in different contexts.
“Galapagos will evaluate whether GLPG1205 will be developed in alternative indications,” the group said.